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INTRODUCTION
Uterine carcinosarcomas are rare biphasic neoplasms composed 
of carcinomatous and sarcomatous components. It accounts 
for almost half of all uterine sarcomas and 1-3% of all uterine 
malignancies. It is known to be highly aggressive, far more ag-
gressive than matched grade 3 endometrioid endo  metrial car-
cinomas. The overall 5-year survival is around 20-35% and the 
5-year survival for stage IV disease is reported to be around 
10% [1]. Especially, the overall survival for stage IVB is expected 
to be very poor, although there are no exact statistics. The au-
thors report a rare case after experiencing long-term survival 
(over 5 years) for stage IVB carcinosarcoma of the uterus. 
CASE REPORT
The menopausal 56 year old female patient (parity, 2-0-0-
2) without specific medical history and history of hormone 
replacement visited the outpatient clinic for vaginal bleeding 
on August 2004. She was diagnosed with a cervical myoma 
2 years ago at a local clinic. Since there was no change in the 
size of the myoma and bleeding, regular follow-up was con-
ducted at the local clinic. Papanicolaou test (PAP) smears has 
remained normal for the recent 2 years. On speculum exam, 
polyps were not observed but an approximately 9 cm sized 
mass occupying the vagina was observed. Since it was diffi-
cult to find the cervical os due to the mass, the endometrium 
was difficult to evaluate properly. Endometrial thickness on 
ultrasound was approximately 3 mm and no specific findings 
were observed. Because postmenopausal vaginal bleeding 
continued for approximately 3 months, and high vascular-
ity of the irregular contoured-mass was observed on Dop-
pler ultrasound, total abdominal hysterectomy and bilateral 
salpingo-oophorectomy was performed due to the possibility 
Case Report
Long-term recurrence-free survival in a patient with 
stage IVB uterine carcinosarcoma
Gun Yoon, Yong-Seok Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Received May 13, 2010, Revised Jul 4, 2010, Accepted Aug 5, 2010
Correspondence to Jeong-Won Lee
Department of Obstetrics and Gynecology, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-




Copyright © 2011. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
www.ejgo.org
Uterine carcinosarcomas are rare and highly aggressive tumors with a poor prognosis. Due to early metastasis and disease pro-
gression, it is known to be far more aggressive than matched grade 3 endometroid endometrial carcinomas. Five-year survival 
for stage IV is reported to be 10% and overall survival for stage IVB is expected to be very poor. The authors report one case 
after experiencing long-term survival (over 5 years) for stage IVB carcinosarcoma of uterus. Total abdominal hysterectomy and 
bilateral salpingo-oophorectomy was performed to 56 year old patient for uterine myoma. On pathology report, uterine carci-
no  sarcoma was diagnosed and image studies were performed. With the impression of stage IVB uterine carcinosarcoma, 6 
cycles of chemotherapy (ifosfamide and cisplatin) was conducted as adjuvant. Up to recently (over 5 years), she maintains good 
performance scale without evidence of tumor recurrence or disease progression.
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of malignancy on August 27, 2004. After incising the tumor 
along the middle border of the anterior uterine wall, a huge 
well circumscribed solid mass was found fully filling the whole 
lower uterus. The mass was slightly friable with bleeding and 
necrosis. An ill-defined scattered necrotic solid mass was ob-
served along the whole myometrial layer. According to the 
pathology report (Fig. 1A), it was consistent with an uterine 
carcinosarcoma (with heterologous components) with nega-
tive resection margin. Extensive lymphatic and vascular inva-
sion were observed on the tumor. Metastasis to both ovaries 
was additionally diagnosed by the pathology (Fig. 1B) despite 
the absence of no gross lesions at the time of surgery. On im-
munohistochemical staining, cytokeratin was positive while 
vimentin, CK20, CD10, epithelial membrane antigen was neg-
ative. 
To identify the metastatic loci, abdominopelvic magetic 
resonance imaging (MRI), positron emission tomography-
computed tomography (PET-CT) and tumor markers (CA-125 
and CA 19-9) were conducted 4 weeks after the operation. On 
MRI, multiple metastatic lymph nodes were observed in the 
pelvic cavity. Two metastatic nodules on the right lobe of the 
liver were observed. Furthermore, additional peritoneal seed-
ing nodules were observed between the right lobe of the liver 
and upper pole of the right kidney, and a soft-tissue mass was 
observed on the vaginal stump. On PET (Fig. 1C), abnormal 
fluorodeoxyglucose (FDG) uptake increase was confirmed on 
the aortocaval, mesenteric, bilateral iliac chain, left obturator 
lymph node, hepatic nodules, and peritoneal seeding nodules. 
The CA-125 was 50.0 U/mL. With the impression of an uterine 
carcinosarcoma stage IVB, we started palliative chemotherapy 
for 6 cycles from September 18, 2004 to January first, 2005; 
5,000 mg/m
2 of ifosfamide (with mesna) and 50 mg/m
2 of cis-
platin. No adjuvant radiotherapy was conducted. During the 
6 cycles of chemotherapy, no serious side effects were found 
and the Eastern Cooperative Oncology Group (ECOG) perfor-
mance scale was 0-1. The tumor marker (CA-125) normalized 
after 1 cycle of chemotherapy. Four weeks after completion of 
chemotherapy, MRI and PET-CT scans were followed-up. The 
lesions mentioned above were almost diminished over 80% 
(partial response by Response Evaluation Criteria In Solid Tu-
Fig. 1. Histologic and radiologic images of 
carcinosarcoma. (A) Pathologic slide for main 
mass (H&E, x400). (B) Pathologic slide for 
ovarian metastasis (H&E, x400). (C) Positron 
emission tomography image (hepatic meta­
stasis and some of peritoneal seeding nodules).Gun Yoon, et al.
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mors [RECIST] criteria). Thereafter, the progress was observed 
every 3 months for the first year and every 6 months thereaf-
ter. No tumor recurrence, distant metastasis and meaningful 
lymph node enlargement has been reported on the image 
studies. Recent PAP smears as well as the tumor marker are 
all normal as of present (June, 2010). Her general condition is 
very tolerable with excellent ECOG performance scale (0-1). 
DISCUSSION
The rarity of this tumor has limited large epidemiologic stud-
ies to report clinical behavior and outcome. Current evidence 
would suggest that carcinosarcomas of the uterus undergo 
full surgical staging and resection of any gross metastatic dis-
ease. Lymph node dissection has not been shown to be thera-
peutic. 
Adjuvant chemotherapy may be beneficial for advanced 
stage. A phase II trial of ifosfamide and mesna in patients with 
advanced or recurrent carcinosarcomas was conducted by the 
Gynecologic Oncologic Group. Ifosfamide was unusually effec-
tive with a total response rate of 32.2% (complete response, 
17.9%; partial response, 14.3%) [2]. The results of a randomized 
study comparing ifosfamide alone versus ifosfamide and pacl-
itaxel in 179 patients with advanced uterine carcinosarcomas 
reported a response rate of 29% with ifosfamide alone and 
45% in combination. The median progression-free and overall 
survival for ifosfamide compared with the combination was 3.6 
vs. 5.8 months, and 8.4 vs. 13.5 months, respectively [3]. The 
results of a relatively large randomized clinical trial comparing 
whole-abdominal radiation (WAR) with three cycles of cispla-
tin, ifosfamide, and mesna (CIM) in 201 patients with stages I 
to IV uterine carcinosarcomas were reported in 2007. The es-
timated crude probability of recurring within 5 years was 58% 
for WAR and 52% for CIM. Adjusting for stage and age, the 
recurrence rate was 21% lower for CIM patients than for WAI 
patients (relative hazard [RH], 0.789; 95% confidence interval 
[CI], 0.530 to 1.176; p=0.245; 2-tail test). The estimated death 
rate was 29% lower among the CIM group (RH, 0.712; 95% CI, 
0.484 to 1.048; p=0.085; 2-tail test). There were no statistically 
significant advantages in the recurrence rate or survival for 
adjuvant CIM over WAI. However, the observed differences 
favored the use of combination chemotherapy [4]. 
The benefit of adjuvant radiotherapy is unclear regarding 
overall survival so far. Some studies have revealed the advan-
tage of radiotherapy for disease specific survival in early-stage 
tumors as well as local control in advanced-stage tumors [5]. 
This is a case report for stage IVB carcinosarcoma of the uter-
us with long-term survival over 5 years. Only chemotherapy 
was performed as adjuvant therapy. Since the data and clini-
cal trial related to prognosis and adjuvant therapy is extremely 
rare, close follow-up of the clinical course of patient seems to 
be critical from the clinical point of view.
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